View Older Stories View More Recent Stories

Dec 21, 2020 07:31AM Biogen (BIIB) Announces EC Grants Marketing Authorization for PLEGRIDY Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
Dec 21, 2020 07:30AM The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
Dec 21, 2020 07:30AM The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
Dec 9, 2020 10:30PM Biogen Files New Drug Application for Aducanumab in Japan
Dec 9, 2020 10:30PM Biogen Files New Drug Application for Aducanumab in Japan
Nov 27, 2020 07:31AM Biogen (BIIB) and Sage Therapeutics (SAGE) Announce Pact to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 27, 2020 07:30AM Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 27, 2020 07:30AM Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 27, 2020 07:30AM Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Nov 18, 2020 07:02AM Samsung Bioepis and Biogen (BIIG) Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis
Nov 18, 2020 07:00AM Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Nov 18, 2020 07:00AM Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Nov 16, 2020 07:30AM Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
Nov 16, 2020 07:30AM Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership
Nov 9, 2020 06:41AM Biogen (BIIB) Confirms Negative FDA Advisory Committee Votes on Aducanumab in Alzheimer's Disease
Nov 6, 2020 08:15PM Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease
Nov 3, 2020 07:35AM Biogen (BIIB) to Present Positive Phase 2 Systemic Lupus Erythematosus Data at ACR
Nov 3, 2020 07:30AM Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
Nov 3, 2020 07:30AM Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
Oct 30, 2020 07:02AM Biogen (BIIB) Announces EMA Accepts Aducanumab Marketing Authorization Application for Alzheimer's Disease
Oct 30, 2020 07:00AM European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
Oct 30, 2020 07:00AM European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
Oct 6, 2020 07:03AM Samsung Bioepis and Biogen (BIIB) Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis
Oct 6, 2020 07:00AM Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Oct 6, 2020 07:00AM Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
Sep 14, 2020 07:30AM Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
Sep 14, 2020 07:30AM Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health
Sep 11, 2020 08:05AM Biogen (BIIB) Says New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of its Industry-Leading MS Portfolio
Sep 11, 2020 08:01AM New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio
Sep 11, 2020 08:01AM New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio
Sep 8, 2020 07:30AM New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
Sep 8, 2020 07:30AM New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS
Aug 7, 2020 07:32AM Biogen (BIIB) Announces FDA Accepts its Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Aug 7, 2020 07:30AM FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Aug 7, 2020 07:30AM FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Aug 6, 2020 08:09AM Biogen (BIIB), Denali (DNLI) to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Aug 6, 2020 08:02AM Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Aug 6, 2020 08:02AM Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases
Jul 24, 2020 04:08PM Biogen (BIIB) to Present Data at Virtual 2020 AAIC Highlighting Comprehensive Approach to Alzheimer's Disease
Jul 24, 2020 04:06PM Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
Jul 24, 2020 04:06PM Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease
Jul 22, 2020 06:32AM Biogen (BIIB) CFO Jeffrey Capello Steps Down, Michael McDonnell Named to Position
Jul 21, 2020 06:00PM Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
Jul 21, 2020 06:00PM Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer
Jul 21, 2020 07:31AM Biogen (BIIB) Begins Phase 4 Study Evaluating Benefit of SPINRAZA (nusinersen) in Patients Treated with Zolgensma (onasemnogene abeparvovec)
Jul 21, 2020 07:30AM Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
Jul 21, 2020 07:30AM Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
Jul 14, 2020 05:53AM Biogen (BIIB) Begins New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 13, 2020 07:31PM Initiation Of New Phase III Clinical Study (AHEAD 3-45) Of BAN2401 Preclinical (Asymptomatic) Alzheimer's Disease
Jul 8, 2020 05:03PM Biogen (BIIB) Announces NEJM Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS
View More Recent Stories View Older Stories